الصفحة الرئيسية>>Signaling Pathways>> Membrane Transporter/Ion Channel>> iGluR>>Sepimostat dimethanesulfonate

Sepimostat dimethanesulfonate

رقم الكتالوجGC61570

يُظهر Sepimostat dimethanesulfonate (FUT-187) نشاطًا وقائيًا للأعصاب عبر عداء مستقبلات NR2B N-methyl-D-aspartate في موقع ربط Ifenprodil للوحدة الفرعية NR2B

Products are for research use only. Not for human use. We do not sell to patients.

Sepimostat dimethanesulfonate التركيب الكيميائي

Cas No.: 103926-82-5

الحجم السعر المخزون الكميّة
5 mg
278٫00
متوفر
10 mg
464٫00
متوفر
25 mg
881٫00
متوفر
50 mg
1437٫00
متوفر
100 mg
2178٫00
متوفر

Tel:(909) 407-4943 Email: sales@glpbio.com

مراجعات العميل

بناء على آراء العملاء.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

Sepimostat dimethanesulfonate (FUT-187) exhibits neuroprotective activity via NR2B N-methyl-D-aspartate receptor antagonism at the Ifenprodil-binding site of the NR2B subunit. Sepimostat dimethanesulfonate inhibits the Ifenprodil binding with a Ki value of 27.7 µM[1].

Sepimostat (1 to 100 nmol/eye, intravitreal injection) exhibits significant neuroprotective effect[1]. Animal Model: Male Sprague Dawley rats weighing 150-300 g[1].

[1]. Masahiro Fuwa, et al. Nafamostat and Sepimostat Identified as Novel Neuroprotective Agents via NR2B N-methyl-D-aspartate Receptor Antagonism Using a Rat Retinal Excitotoxicity Model. Sci Rep. 2019 Dec 31;9(1):20409.

مراجعات

Review for Sepimostat dimethanesulfonate

Average Rating: 5 ★★★★★ (Based on Reviews and 10 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Sepimostat dimethanesulfonate

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.